Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization

Jihwang Lee, Na Kyung Ryoo, Hyounkoo Han, Hye Kyoung Hong, Ji Yeon Park, Sang Jun Park, Yong Kyu Kim, Changbeom Sim, Kwang Meyung Kim, Se Joon Woo, Kyu Hyung Park, Hyuncheol Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 ± 43.27 nm) and negative charge (-4.98 ± 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.

Original languageEnglish
Pages (from-to)1988-1995
Number of pages8
JournalMolecular Pharmaceutics
Volume13
Issue number6
DOIs
Publication statusPublished - 2016 Jun 6
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Vascular Endothelial Growth Factor A
Retina
Intravitreal Injections
Small Interfering RNA
Lasers
Light Coagulation
Poisons
Macular Degeneration
Protein Biosynthesis
Hyaluronic Acid
Therapeutics
Technology
In Vitro Techniques

Keywords

  • choroidal neovascularization
  • intravitreal injection
  • polyplex
  • polysiRNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Lee, J., Ryoo, N. K., Han, H., Hong, H. K., Park, J. Y., Park, S. J., ... Kim, H. (2016). Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization. Molecular Pharmaceutics, 13(6), 1988-1995. https://doi.org/10.1021/acs.molpharmaceut.6b00148

Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization. / Lee, Jihwang; Ryoo, Na Kyung; Han, Hyounkoo; Hong, Hye Kyoung; Park, Ji Yeon; Park, Sang Jun; Kim, Yong Kyu; Sim, Changbeom; Kim, Kwang Meyung; Woo, Se Joon; Park, Kyu Hyung; Kim, Hyuncheol.

In: Molecular Pharmaceutics, Vol. 13, No. 6, 06.06.2016, p. 1988-1995.

Research output: Contribution to journalArticle

Lee, J, Ryoo, NK, Han, H, Hong, HK, Park, JY, Park, SJ, Kim, YK, Sim, C, Kim, KM, Woo, SJ, Park, KH & Kim, H 2016, 'Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization', Molecular Pharmaceutics, vol. 13, no. 6, pp. 1988-1995. https://doi.org/10.1021/acs.molpharmaceut.6b00148
Lee, Jihwang ; Ryoo, Na Kyung ; Han, Hyounkoo ; Hong, Hye Kyoung ; Park, Ji Yeon ; Park, Sang Jun ; Kim, Yong Kyu ; Sim, Changbeom ; Kim, Kwang Meyung ; Woo, Se Joon ; Park, Kyu Hyung ; Kim, Hyuncheol. / Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization. In: Molecular Pharmaceutics. 2016 ; Vol. 13, No. 6. pp. 1988-1995.
@article{ea565bbfc93449ec94c9ed5dc05d3b62,
title = "Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization",
abstract = "Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 ± 43.27 nm) and negative charge (-4.98 ± 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.",
keywords = "choroidal neovascularization, intravitreal injection, polyplex, polysiRNA",
author = "Jihwang Lee and Ryoo, {Na Kyung} and Hyounkoo Han and Hong, {Hye Kyoung} and Park, {Ji Yeon} and Park, {Sang Jun} and Kim, {Yong Kyu} and Changbeom Sim and Kim, {Kwang Meyung} and Woo, {Se Joon} and Park, {Kyu Hyung} and Hyuncheol Kim",
year = "2016",
month = "6",
day = "6",
doi = "10.1021/acs.molpharmaceut.6b00148",
language = "English",
volume = "13",
pages = "1988--1995",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization

AU - Lee, Jihwang

AU - Ryoo, Na Kyung

AU - Han, Hyounkoo

AU - Hong, Hye Kyoung

AU - Park, Ji Yeon

AU - Park, Sang Jun

AU - Kim, Yong Kyu

AU - Sim, Changbeom

AU - Kim, Kwang Meyung

AU - Woo, Se Joon

AU - Park, Kyu Hyung

AU - Kim, Hyuncheol

PY - 2016/6/6

Y1 - 2016/6/6

N2 - Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 ± 43.27 nm) and negative charge (-4.98 ± 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.

AB - Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 ± 43.27 nm) and negative charge (-4.98 ± 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.

KW - choroidal neovascularization

KW - intravitreal injection

KW - polyplex

KW - polysiRNA

UR - http://www.scopus.com/inward/record.url?scp=84973650214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973650214&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.6b00148

DO - 10.1021/acs.molpharmaceut.6b00148

M3 - Article

C2 - 27173745

AN - SCOPUS:84973650214

VL - 13

SP - 1988

EP - 1995

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 6

ER -